Joyce Sensmeier

Clinical Data Interchange Standards Consortium, Inc. is a non-profit organization that creates clarity in clinical research by developing and advancing data standards of the highest quality. CDISC standards are required by the United States Food and Drug Administration (FDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), recommended by the China National Medical Products Administration (NMPA), and adopted by the world's leading research organizations. These standards enable the accessibility, interoperability, and reusability of data, maximizing the value of data for more efficient and meaningful research that has invaluable impact on health. CDISC actively collaborates with Europe's Innovative Medicines Initiative and is strategically positioned as a standards governance body that supports and maintains standards not only for clinical research but also for public health. The American company was founded by Rebecca Daniels Kush and David A. Evans has been the CEO of the company since 2021.

Clinical Data Interchange Standards Consortium, Inc. is a non-profit organization that creates clarity in clinical research by developing and advancing data standards of the highest quality. CDISC standards are required by the United States Food and Drug Administration (FDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), recommended by the China National Medical Products Administration (NMPA), and adopted by the world's leading research organizations. These standards enable the accessibility, interoperability, and reusability of data, maximizing the value of data for more efficient and meaningful research that has invaluable impact on health. CDISC actively collaborates with Europe's Innovative Medicines Initiative and is strategically positioned as a standards governance body that supports and maintains standards not only for clinical research but also for public health. The American company was founded by Rebecca Daniels Kush and David A. Evans has been the CEO of the company since 2021.

Clinical Data Interchange Standards Consortium, Inc. is a non-profit organization that creates clarity in clinical research by developing and advancing data standards of the highest quality. CDISC standards are required by the United States Food and Drug Administration (FDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), recommended by the China National Medical Products Administration (NMPA), and adopted by the world's leading research organizations. These standards enable the accessibility, interoperability, and reusability of data, maximizing the value of data for more efficient and meaningful research that has invaluable impact on health. CDISC actively collaborates with Europe's Innovative Medicines Initiative and is strategically positioned as a standards governance body that supports and maintains standards not only for clinical research but also for public health. The American company was founded by Rebecca Daniels Kush and David A. Evans has been the CEO of the company since 2021.

Clinical Data Interchange Standards Consortium, Inc. is a non-profit organization that creates clarity in clinical research by developing and advancing data standards of the highest quality. CDISC standards are required by the United States Food and Drug Administration (FDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), recommended by the China National Medical Products Administration (NMPA), and adopted by the world's leading research organizations. These standards enable the accessibility, interoperability, and reusability of data, maximizing the value of data for more efficient and meaningful research that has invaluable impact on health. CDISC actively collaborates with Europe's Innovative Medicines Initiative and is strategically positioned as a standards governance body that supports and maintains standards not only for clinical research but also for public health. The American company was founded by Rebecca Daniels Kush and David A. Evans has been the CEO of the company since 2021.

Clinical Data Interchange Standards Consortium, Inc. is a non-profit organization that creates clarity in clinical research by developing and advancing data standards of the highest quality. CDISC standards are required by the United States Food and Drug Administration (FDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), recommended by the China National Medical Products Administration (NMPA), and adopted by the world's leading research organizations. These standards enable the accessibility, interoperability, and reusability of data, maximizing the value of data for more efficient and meaningful research that has invaluable impact on health. CDISC actively collaborates with Europe's Innovative Medicines Initiative and is strategically positioned as a standards governance body that supports and maintains standards not only for clinical research but also for public health. The American company was founded by Rebecca Daniels Kush and David A. Evans has been the CEO of the company since 2021.

Clinical Data Interchange Standards Consortium, Inc. is a non-profit organization that creates clarity in clinical research by developing and advancing data standards of the highest quality. CDISC standards are required by the United States Food and Drug Administration (FDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), recommended by the China National Medical Products Administration (NMPA), and adopted by the world's leading research organizations. These standards enable the accessibility, interoperability, and reusability of data, maximizing the value of data for more efficient and meaningful research that has invaluable impact on health. CDISC actively collaborates with Europe's Innovative Medicines Initiative and is strategically positioned as a standards governance body that supports and maintains standards not only for clinical research but also for public health. The American company was founded by Rebecca Daniels Kush and David A. Evans has been the CEO of the company since 2021.